TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03682887

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon PV isolation group
Description: 1. Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~2. Target number of subjects: 278 (138 per group)~3. Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoballoon PV isolation with Additional RA linear ablation group
Description: 1. Prospective randomization (cryoballoon PV isolation group vs. cryoballoon PV isolation group with additional RA linear ablation group) (Using the Python program, a random number module is imported with the import random syntax, and the random number table for the two groups is created.)~2. Target number of subjects: 278 (138 per group)~3. Rhythm FU : ECG during every visit (1, 3, 6, and 12 months, and then every 6 months thereafter or upon the recurrence of symptoms after AFCA) and 24-h Holter monitor recording at 3 and 6 months and every 6 months thereafter.~4. Anticoagulant therapy followed by 2014 ACC/AHA/ESC guidelines~5. All complications in each group will be evaluated including the re-hospitalization rate, major cardiovascular event, and mortality rate.
Study: NCT01529684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: radio-labeled OSI-906
Description: Part A: oral solution of 14C-OSI-906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Part B: oral tablets OSI-906
Study: NCT00669396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper T380 IUD
Description: Copper T380 IUD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel
Description: 1.5 mg
Study: NCT02785484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label with constituent disclosure message
Description: Labels with constituent disclosure messages that include text about chemicals in cigarette smoke and health effects of the chemicals will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 disclosures selected at random; at the week 3 visit, they will get one of the 2 remaining disclosures selected at random, and at the week 4 visit they will get the remaining disclosure. Study investigators developed the text and design of these labels.

Intervention type: OTHER
Group type: OTHER
Intervention: Label with litter message
Description: Labels with litter messages that include text about littering cigarette butts will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 litter messages selected at random; at the week 3 visit, they will get one of the 2 remaining litter message selected at random, and at the week 4 visit they will get the remaining litter message. Study investigators developed the text and design of these labels.
Study: NCT03599076

Intervention type: OTHER
Intervention: HD Wear
Description: Wearable sensor system for monitoring Huntington's chorea during activities of daily living

Intervention type: OTHER
Intervention: HD Wear
Description: Wearable sensor system for monitoring Huntington's chorea during activities of daily living

Intervention type: OTHER
Intervention: HD Wear
Description: Wearable sensor system for monitoring Huntington's chorea during activities of daily living
Study: NCT05095285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swaddling
Description: * Babies in this group were wrapped with a white cheesecloth 2 minutes before ES in addition to incubator cover and nesting.~* Common procedure steps:~  * Legal representatives of the infants will sign an informed consent form.~ * İncubator cover and nesting~ * Endotracheal suction(ES) was performed in the supine position.~ * ES was done at the time of care the baby needed.~ * No painful procedure was applied until 2 hours before ES and 15 minutes after ES.~ * Aspiration was performed sterile at 80 mmHg pressure.~ * A second nurse assisted in the suction process and the procedure took no more than 15 seconds.~ * The amount of oxygen taken by the baby was increased by 10% 30 seconds before the suction procedure and returned to its original value 60 seconds after the procedure.~ * Beginning 3 minutes before the ES procedure, during the procedure and until 15 minutes after the procedure, the infants' behaviors and bedside monitor indicators were video recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oropharyngeal colostrum
Description: * Common procedure steps~* In addition to incubator cover and nesting, babies in this group were given 0.4 ml of colostrum with an insulin injector on the inside of the cheeks and on the tongue.
Study: NCT01418105

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Videofluroscopic swallow study (VFSS)
Description: Barium, radiation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical spine isometric exercises
Description: patients with cervical scoliosis will execute isometric exercises of the cervical spine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fiberoptic endoscopic esophageal study (FEES)
Description: food for swallowing
Study: NCT02963818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone breathalyzer device/app use
Description: Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC estimator app use
Description: Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messaging procedure
Description: Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
Study: NCT00420537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: cyclosporine trough levels between 100 and 150
Study: NCT04585945

Intervention type: DIAGNOSTIC_TEST
Intervention: Positive for SARS-CoV-2 infection
Description: Patients that have a positive test for SARS-CoV-2 infection during pregnancy, including at the time of delivery.
Study: NCT03194685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10101-01
Description: FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10101-01
Description: FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10101-01
Description: FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10101-01
Description: FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached.
Study: NCT00420537

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: cyclosporine trough levels between 40 and 90 ng/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: mycophenolate with low doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Study: NCT06240286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting workstation
Description: Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station in a seated position.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing workstation
Description: Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while standing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping workstation
Description: Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while utilizing a stepper.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking workstation
Description: Subjects will conduct reasoning, memory, concentration, and fine motor skills (neurocognitive function) assessments on a computer station while walking on a treadmill.
Study: NCT00404911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MFG therapy
Description: MFG includes 16 weekly group therapy sessions for families with children who have ODD or CD. Sessions will include adult caregivers and all children over age 6. Each session will follow the same procedures, and will proceed through the following stages: creating social networks; information exchange; group discussions; individual family practice; and homework assignment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants assigned to standard care will receive treatment that is traditionally offered to outpatients. Participants in the MFG program will also receive standard care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants assigned to standard care will receive treatment that is traditionally offered to outpatients. Participants in the MFG program will also receive standard care.
Study: NCT01078532

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMART PHR
Description: Patient receives an active PHR

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: Usual passive PHR
Study: NCT01715935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
Study: NCT02373657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: instruction in soap-making and hygiene education
Study: NCT01880463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids (fish oil)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids (fish oil)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Study: NCT02892279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diesel exhaust exposure
Description: Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute diesel exhaust via mask.
Study: NCT01519479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Consultation
Description: Intervention patient would receive an inpatient palliative care consultation to focus on comprehensive symptom assessment, create goals of care/treatment plan which include recommendations and referrals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group would receive usual care and could receive a palliative consult if ordered by the treating provider
Study: NCT03713450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control with imaging guidance
Description: Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control without imaging guidance
Description: Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure not using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile).
Study: NCT03027596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Study: NCT02033408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB (antibiotics)
Description: 1. PO Vancomycin 250mgX4/d for 3 weeks~2. PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~3. PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug.

Intervention type: DRUG
Group type: OTHER
Intervention: AB (antibiotics)
Description: 1. PO Vancomycin 250mgX4/d for 3 weeks~2. PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~3. PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug.

Intervention type: DRUG
Group type: OTHER
Intervention: CS (corticosteroids) Only
Description: 1. methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~2. PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CS (corticosteroids) Only
Description: 1. methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~2. PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks
Study: NCT03624231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab (75 mg) for up to 4 doses/cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)
Study: NCT02842307

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture implemented by senior acupuncturists
Description: Manual acupuncture once per day. No limitation on points, manipulations and time per session. Senior acupuncturists have to have more than 15 years of acupuncture clinical practice experience.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture implemented by junior acupuncturists
Description: Manual acupuncture once per day. No limitation on points, manipulations and time per session. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual acupuncture on P6 point
Description: Manual acupuncture implemented by junior acupuncturists once per day. P6 point, bilaterally, should achieve deqi sensation by even manipulations. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
Study: NCT00804245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needle biopsy
Description: Biopsy of positive findings found on CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET-CT scans supplemented with 11C-Choline tracer
Description: Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
Study: NCT03401554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: titanium mesh
Description: closing the lateral window for maxillary sinus floor elevation with titanium mesh
Study: NCT01972139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Angiography
Description: Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
Study: NCT03178201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: Treatment will be self-administered on an outpatient basis. Patients will take TGR-1202 800 mg, oral, one tablet daily on a continuous basis. Each cycle lasts 28 days.
Study: NCT03821207

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The exercise group
Description: The students will make exercise during the first three days of the menstrual period

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The abdominal massage group
Description: The students will make abdominal massage during the first three days of the menstrual period

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The students will nor massage or exercise
Study: NCT00969254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pílulas de Lussen
Description: Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pílulas de Lussen®~\*\* Drug B: placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridium®
Description: Take one dragee of drug A\* and one dragee of drug B\*\* every 8 hours for three days.~\* Drug A: Pyridium®~\*\* Drug B: placebo.
Study: NCT03867188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: A 25 gauge or larger bore needle will be used to inject the liposomal bupivacaine at the site of operation following the prescription guidelines provided by Exparel®. The maximum dose allowable for this study is 266mg or 20 mL as indicated in the FDA package insert.
Study: NCT01763047

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: To be worn in a daily wear modality for a minimum of 6 hours per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: To be worn in a daily wear modality for a minimum of 6 hours per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: Lenses will be worn in a reuseable modality; cleaned and disinfected each night.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
Study: NCT05166174

Intervention type: PROCEDURE
Intervention: Transvaginal ultrasound in the third trimester pregnancy
Description: Ultrasonographic transvaginal exam in patients at third trimester pregnancy (34-38 weeks of gestation)

Intervention type: PROCEDURE
Intervention: Transvaginal ultrasound in the third trimester pregnancy
Description: Ultrasonographic transvaginal exam in patients at third trimester pregnancy (34-38 weeks of gestation)
Study: NCT01605136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: One 16mg subcutaneous implant every 2 months for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo subcutaneous implant every 2 months for 6 months
Study: NCT04258774

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Dioxide
Description: The study team will administer inhaled carbon dioxide to the participants during an MRI at a level

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon Dioxide
Description: The study team will administer inhaled carbon dioxide to the participants during an MRI at a level
Study: NCT00175435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Resiquimod gel
Description: 3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator
Study: NCT03731234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance
Study: NCT02321501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study: NCT03401554

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: collagen membrane
Description: closing the lateral window for maxillary sinus floor elevaion with collagen membrane
Study: NCT00175435

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Resiquimod gel
Description: 3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Resiquimod gel
Description: 3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
Study: NCT02321501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02809443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5700
Description: GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5700
Description: GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus